FORM NAMCS-CCS

U.S. DEPARTMENT OF COMMERCE
Economics and Statistics Administration
U.S. CENSUS BUREAU
ACTING AS DATA COLLECTION AGENT FOR THE
U.S. Department of Health and Human Services
Centers for Disease Control and Prevention
National Center for Health Statistics

NATIONAL AMBULATORY MEDICAL CARE SURVEY 2008 CERVICAL CANCER SCREENING SUPPLEMENT

NOTICE – Public reporting burden of this collection of information is estimated to average 15 minutes per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing the collection of information. An agency may not conduct or sponsor, and a person is not required to respond to a collection of information unless it displays a currently valid OMB control number. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden to: CDC/ATSDR Reports Clearance Officer; 1600 Clifton Road, MS D-74, Atlanta, GA 30333, ATTN: PRA(0920-0234).

Assurance of Confidentiality – All information which would permit identification of an individual, a practice, or an establishment will be held confidential, will be used by persons engaged in and for the purpose of the survey and will not be disclosed or released to other persons or used for any other purpose without the consent of the individual or the establishment in accordance with section 308(d) of the Public Health Service Act (42 USC 242m).

BACKGROUND INFORMATION

0010	A. Provider's specialty (Mark (X) only ONE.) 1 ☐ General/Family 2 ☐ Internal 3 ☐ OB/ 4 ☐ CHC Mid-level Practice Medicine GYN Provider		B.	Census	contact	name				
0020	C. Provider's serial number	0025	D.	Census contact telephor		ea code N	lumber			
INT	The Centers for Disease Control and Prevention is conducting a special survey on cervical cancer screening performed in community health centers and private office settings. Please answer the following questions. We appreciate your time on this important public health concern.									
1	Does your practice use any of the following methods to screecervical cancer? Mark (X) all that apply. Conventional Pap test (Definition – Smear spread on glass slite)	ide and	d fixe		Mark (Every 2 years	Every 3 years	More than 3 years	No routine interval recom- mended	
1 Yes – How often does your practice routinely screen women using this method? 2 No 3 Unknown Continue with item 1b						2	з□	4	5	
1	Liquid-based cytology (Definition – Specimen suspended in lied of the suspended of the suspended in lied of the suspended	quid so	olutio	n) →	 	2	3 🗆	4 🗆	5 🗆	
	Other – Specify									
0065	1 Yes – How often does your practice routinely screen worthis method? 2 No 3 Unknown	men us	sing		 1	2	3	4	5 🗆	
0050	Does your practice perform colposcopy? 1 ☐ Yes 2 ☐ No 3 ☐ Unknown									

0070 b.	Does your practice ever order or collect the Human Papillomavirus (HPV) DNA test? 1 Yes - Go to item 3b 2 No - SKIP to item 3c 3 Not aware of HPV DNA test 4 Unknown Which of the following HPV DNA tests are ordered or collected in your practice? Mark (X) all that apply. 1 High risk (HR) HPV DNA test 2 Low risk (LR) HPV DNA test	0085	If a patient's Pap test result is borderline or abnormal, does your practice routinely order an HPV DNA test to be performed on that sample (commonly called reflex HPV DNA testing)? (An HPV DNA test may be run on the same liquid-based medium as the Pap test or an HPV DNA test specimen may be collected at the same time as the conventional Pap test.) 1 Yes – Go to item 4b 2 No 3 Unknown 3 SKIP to item 5a
	3 □ Not aware there was a high risk or low risk HPV DNA test 4 □ Type-specific HPV DNA test 5 □ Unknown		For which borderline or abnormal Pap test result would your practice order or collect a reflex HPV DNA test? Mark (X) all that apply. 1 □ ASC-US (atypical squamous cells of undetermined significance)
0080	 Why is the HPV DNA test not ordered or collected in your practice? – Mark (X) all that apply. 1 ☐ My practice does not see the types of patients for whom the HPV DNA test is indicated. 2 ☐ My practice uses other tests, procedures, or examination methods to manage patients for whom the HPV DNA test is indicated. 3 ☐ The patients in my practice have timely access to 	n	 ASC-H (atypical squamous cells of undetermined significance – cannot exclude high-grade intraepithelial lesion) LSIL (low-grade squamous intraepithelial lesion, encompassing mild dysplasia/CIN1) HSIL (high-grade squamous intraepithelial lesion, moderate dysplasia/CIN2, severe dysplasia/CIN3, and carcinoma in situ) AGC (atypical glandular cells)
	colposcopy. 4 Assessing patients' HPV infection status is not a priority at my practice. 5 The labs affiliated with my practice do not offer the HPV DNA test. 6 The health plans or health systems affiliated with	0095	For which patients does your practice usually order reflex HPV DNA testing? – Mark (X) all that apply. 1 □ Women under 21 years old 2 □ Women 21 years old to 29 years old 3 □ Women 30 years old and over 4 □ Other – Specify ✓
	my practice do not recommend the HPV DNA test 7 The HPV DNA test is not a reimbursed or covered service for most patients in my practice.	5010	
	8 ☐ Discussing cervical cancer screening in the contex of an STD is avoided in my practice.	5a.	Does your practice routinely recall patients to come back for a second sample collection for an HPV DNA test if their Pap test is abnormal or borderline (recall testing)?
	 Notifying or counseling patients about positive HP DNA test results would take too much time. Notifying or counseling patients about positive HP DNA test results might make clinicians in my practice feel uncomfortable. Notifying or counseling patients about positive HP DNA test results might make patients in my practice feel uncomfortable, angry, or upset. 	/ b.	1 ☐ Yes – Go to item 5b 2 ☐ No 3 ☐ Unknown } SKIP to item 6a on page 3 For which abnormal or borderline Pap test result would your practice recall a patient for an HPV DNA test? Mark (X) all that apply.
	SKIP to item 7 on page 3.		2 ☐ ASC-H (atypical squamous cells of undetermined significance – cannot exclude high-grade intraepithelial lesion) 3 ☐ LSIL (low-grade squamous intraepithelial lesion, encompassing mild dysplasia/CIN1) 4 ☐ HSIL (high-grade squamous intraepithelial lesion, moderate dysplasia/CIN2, severe dysplasia/CIN3, and carcinoma in situ) 5 ☐ AGC (atypical glandular cells)

Page 2 FORM NAMCS-CCS (11-29-2007)

6a.	Does your practice routinely order or collect an HPV DNA test at the same time as the Pap test as part of routine cervical cancer screening (commonly called adjunct HPV testing or cotesting)?										
0110	1 ☐ Yes – Go to item 6b										
	2 No 3 Unknown SKIP to item 7										
b.	For which patients does your practice routinely order or collect an HPV DNA test along with the Pap test (commonly called adjunct HPV testing or cotesting)? Mark (X) all that apply.										
0115											
	2 Women 21 years old to 29 years old										
	$_3\square$ Women 30 years old and over $_4\square$ Women who request the test for cervical cancer screening										
	₅ Women who request the test to check their HPV infection status										
	6 ☐ Other – <i>Specify</i>										
5015											
7.	7. Given the following screening histories, when would your practice recommend that a woman between 30 and 60 years of age return for her next Pap test?										
			 -		For ea	ch of the fo	llowing scen	arios, mar	k (X) only	ONE for ea	
i	n pa exclı	ap test results st 5 years uding current nal results)	Current HPV DNA test results	Current Pap test result	No follow-up needed	Less than 6 months	6 months to less than 1 year	1 year	2 years	3 years or more	Have no experience with this type of patient or test
0120	(a)	Two consecutive normal Pap tests	Has not had test	Normal	1 🗆	2	3 🗆	4	5 🗆	6 🗆	7 🗆
0125	(b)	Two consecutive normal Pap tests	Negative	Normal	1	2	3 🗆	4	5 🗌	6	7
0130	(c)	Two consecutive normal Pap tests	 Positive	Normal	1	2	з 🗆	4	5 🗌	6 🗆	7
0135	(d)	Has not had a Pap test	 Negative	Normal	1	2	з□	4	5 🗆	6 🗆	7 🗆
0140	(e)	Has not had a Pap test	Positive	Normal	1	2	3 🗆	4	5	6 🗆	7 🗆
0145	(f)	Abnormal Pap test	 Negative 	Normal	1	2	з 🗆	4	5	6	7 🗌
0150	(g)	Abnormal Pap test	Positive	Normal	1 🗌	2	3 🗆	4	5	6	7
OUTSTIONS SALABOUT THE HEW VACCINE											
8.	8. How often does your practice use an HPV test to determine who should get the HPV vaccine? <i>Mark (X) only one.</i>										
	1 ☐ Rarely or never										
	2 ☐ Sometimes										
	3 ☐ Usually 4 ☐ Always or almost always										
	5 □ Do not recommend the HPV vaccine <i>−SKIP to item 10.</i>										
/)										

FORM NAMCS-CCS (11-29-2007) Page 3

9.	As it relates to the HPV vaccine,								
	how often does your practice -	Rarely or	Sometimes	Usually	Always or almost	Unknown/Not applicable/			
	Mark (X) only ONE for each row.	never	Sometimes	Osually	always	Do not ask			
0120	 Use the number of sexual partners to determine who should get the HPV 		_			_			
0405	vaccine?	1 🗆	2 🗆	3 🗆	4	5			
0125	b. Perform a Pap test to determine who should get the HPV vaccine?	1 🗆	2 🗆	3□	4 🗆	5 🗌			
0130	c. Recommend the HPV vaccine to females with a history of an abnormal								
	Pap test result (ASC-US or higher)?	1 🗆	2	3 🗆	4 🗆	5			
0135	d. Recommend the HPV vaccine to females with a positive HPV test?	1 🗆	2 🗆	з□	4 🗆	5 🗌			
10.	Will your practice's cervical cancer screening management procedures change for female been fully vaccinated with the HPV vaccine?	s who have	nave 1 Yes 2 No - SKIP to item 14						
11.	How will your practice determine when to stacervical cancer screening for fully HPV vacc	aga ag nan UDV							
	females?		1						
	Mark (X) all that apply.		Specify		→				
			2□ At a late Specify		→				
			2□ By onset of s	exual activity –					
		· 	How many ye onset of sexu	ear(s) since ual activity?———	→				
			3 Will not be so	creening fully HP\	/ vaccinated fema	ales			
12	How often will your practice routinely screen	for convical	1 Annually						
12.	cancer among females that have been fully vaccinated 2 Every 2-3 years								
	4 ☐ Greater than every 5 years								
			5 ☐ Will not be so		V vaccinated fema	ales			
12	Will your practice be using the HPV DNA te	et for	6 Unknown						
	managing abnormal cytology for females that have been fully vaccinated with the HPV vaccine?								
14.	Please indicate to what extent you agree, di with each statement. Please respond to both	Agree	Disagree	Unsure					
	There will be fewer numbers of abnorm among vaccinated females.		1 🗆	2	з□				
	There will be fewer referrals for colpose vaccinated females.	1 🗆	2	з□					
15.	15. The Centers for Disease Control and Prevention (CDC) funds state health departments to provide breast and cervical cancer screening services to low income women through the National Breast and Cervical Cancer Early Detection Program (Title XV). The state health departments contract out the screening services to physicians and other health care providers. Is this practice currently participating in this state or national screening program?								
0155	1 ☐ Yes 2 ☐ No 3 ☐ Unknown								
	For purposes of this survey, which of the fo	llowing catego	•		. , .				
0160	1 ☐ Physician 2 ☐ Physician assistant/ Nurse practitioner/ Nu	rse midwife	3 ☐ Registered nur	rse 4 Other	OIIICE STATT				

CLOSING STATEMENT

Thank you for completing this special survey. We appreciate your time and cooperation.

Page 4 FORM NAMCS-CCS (11-29-2007)